Page last updated: 2024-08-25

buparvaquone and Leishmaniasis, Cutaneous

buparvaquone has been researched along with Leishmaniasis, Cutaneous in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Croft, SL; Garnier, T; Järvinen, T; Koskinen, A; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J1
Adewusi, O; Adriana de Jesus, J; Auxiliadora Dea-Ayuela, M; Bolas-Fernandez, F; Dalastra Laurenti, M; Felipe Domingues Passero, L; Lalatsa, A; Serrano, DR; Statts, L1
Awan, MM; Jamal, Q; Khan, NH; Shah, A; Sutherland, C; Wahid, S1
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA1
Brown, MB; Croft, SL; Garnier, T; Järvinen, T; Lawrence, MJ; Mäntylä, A1
Brown, M; Croft, S; Garnier, T; Järvinen, T; Lawrence, J; Mäntylä, A1

Reviews

1 review(s) available for buparvaquone and Leishmaniasis, Cutaneous

ArticleYear
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
    Expert opinion on drug delivery, 2012, Volume: 9, Issue:9

    Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption

2012

Other Studies

5 other study(ies) available for buparvaquone and Leishmaniasis, Cutaneous

ArticleYear
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
    Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1

    Topics: Administration, Oral; Administration, Topical; Alkaline Phosphatase; Animals; Antiprotozoal Agents; Cricetinae; Female; Humans; Hydrolysis; In Vitro Techniques; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Naphthoquinones; Organophosphates; Permeability; Prodrugs; Skin; Solubility; Water

2004
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis.
    International journal of pharmaceutics, 2020, Oct-15, Volume: 588

    Topics: Animals; Antiprotozoal Agents; Hydrogels; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Naphthoquinones

2020
In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
    Experimental parasitology, 2015, Volume: 154

    Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line, Tumor; Child; Humans; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages; Male; Meglumine; Meglumine Antimoniate; Naphthoquinones; Organometallic Compounds; Pakistan; Parasitic Sensitivity Tests

2015
Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
    The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Administration, Cutaneous; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Ethanol; Female; Humans; In Vitro Techniques; Leishmaniasis, Cutaneous; Melanins; Mice; Mice, Inbred BALB C; Myristates; Naphthoquinones; Organophosphates; Polyethylene Glycols; Prodrugs; Propylene Glycol; Skin; Skin Absorption

2007
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4

    Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Female; Leishmania donovani; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Naphthoquinones; Prodrugs; Skin

2007